BHSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
BIOHARVEST SCIENCES INC.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 40-F on Mar 31, 2026
$1.80−0.05 (-2.70%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Bioharvest Sciences statistics
Financials through Dec 31, 2025, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Bioharvest Sciences | Industry median |
|---|---|---|
| Market Cap | $40.80M | $164.85M |
| Enterprise Value | $17.92M | $87.06M |
| PS Ratio | 1.18 | 3.60 |
| PB Ratio | 1.60 | 2.03 |
| P/TBV Ratio | 1.60 | 2.31 |
Enterprise value
| Measure | Bioharvest Sciences | Industry median |
|---|---|---|
| EV / Sales | 0.52 | 2.43 |
Income (trailing twelve months)
| Measure | Bioharvest Sciences | Industry median |
|---|---|---|
| Revenue | $34.51M | $57.94M |
| Gross Profit | $20.48M | $90.47M |
| Operating Income | -$5.58M | -$21.44M |
| Pretax Income | -$11.06M | -$14.45M |
| Net Income | -$11.14M | -$22.46M |
| EBITDA | -$3.95M | -$16.91M |
Margins
| Measure | Bioharvest Sciences | Industry median |
|---|---|---|
| Gross Margin | 59.3% | 52.3% |
| Operating Margin | -16.2% | -44.5% |
| Pretax Margin | -32.0% | -13.0% |
| Profit Margin | -32.3% | -39.2% |
| EBITDA Margin | -11.4% | -31.3% |
| FCF Margin | -27.8% | -8.85% |
Returns
| Measure | Bioharvest Sciences | Industry median |
|---|---|---|
| Return on Equity (ROE) | -83.2% | -53.1% |
| Return on Assets (ROA) | -30.6% | -41.0% |
| Return on Invested Capital (ROIC) | -162.6% | -32.0% |
| Return on Capital Employed (ROCE) | -13.9% | -37.8% |
Growth
| Measure | Bioharvest Sciences | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 37.0% | 6.01% |
Balance sheet
| Measure | Bioharvest Sciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $23.03M | $62.42M |
| Total Debt | $149.00K | $120.13M |
| Net Cash (Debt) | $22.88M | $15.68M |
| Net Cash Per Share | $1.01 | $0.66 |
| Equity (Book Value) | $25.45M | $48.79M |
| Book Value Per Share | $1.12 | $1.36 |
| Tangible Book Value | $25.45M | $23.06M |
| Working Capital | $22.82M | $75.77M |
Financial position
| Measure | Bioharvest Sciences | Industry median |
|---|---|---|
| Current Ratio | 3.97 | 3.30 |
| Quick Ratio | 3.25 | 2.39 |
| Debt / Equity | 0.01 | 0.51 |
Cash flow (trailing twelve months)
| Measure | Bioharvest Sciences | Industry median |
|---|---|---|
| Operating Cash Flow | -$7.23M | -$12.35M |
| Capital Expenditures | -$2.36M | -$1.06M |
| Free Cash Flow | -$9.58M | -$20.28M |
| FCF Per Share | -$0.42 | -$0.42 |
Efficiency
| Measure | Bioharvest Sciences | Industry median |
|---|---|---|
| Asset Turnover | 0.95 | 0.38 |
| Inventory Turnover | 3.42 | 2.67 |
Dividends and yields
| Measure | Bioharvest Sciences | Industry median |
|---|---|---|
| Earnings Yield | -27.3% | -22.7% |
| FCF Yield | -23.5% | -9.07% |
| Buyback Yield | -44.8% | -0.73% |
| Shareholder Yield | -44.8% | 0.00% |
Shares
| Measure | Bioharvest Sciences | Industry median |
|---|---|---|
| Shares Outstanding | 22,666,800 | 58,179,650 |
| Float | 22,666,800 | 49,173,100 |
| Shares Held by Insiders | 0.00% | 11.6% |
| Shares Held by Institutions | 7.42% | 59.4% |
Taxes
| Measure | Bioharvest Sciences | Industry median |
|---|---|---|
| Income Tax | -$76.00K | $91.50K |
Scores
| Measure | Bioharvest Sciences | Industry median |
|---|---|---|
| Altman Z-Score | -1.14 | -0.24 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Bioharvest Sciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.